Literature DB >> 8102920

The characterization of peritoneal and pleural exudate cells from malignant effusions.

M Oka1, S Yoshino, S Hazama, K Shimoda, T Suzuki.   

Abstract

The immune function of peripheral blood cells and cells from the pleural and abdominal effusions of patients with advanced cancer was compared to that of peripheral blood cells from controls. The parameters examined included lymphocyte subsets, natural killer (NK) cell activity, and anti-Daudi and lymphokine-activated killer (LAK) cell activity. The percentage of CD4+ pleural and peritoneal exudate cells (PEC) was significantly higher than the percentage of peripheral blood mononuclear cells (PBMC) in the patients. The percentage of CD8+CD11+ PEC and PBMC, being the suppressor T-cells, of the patients was increased compared with controls, while the percentage of CD8+CD11- PEC, being the cytotoxic T-cells, was identical to the PBMC of both patients and controls. The NK activity of PEC was significantly lower than that of PBMC in both patients and controls, and there was no correlation between the NK activity of PBMC and PEC. Although the anti-Daudi activity of PEC was markedly low, LAK cells with high activity could be induced by culture with interleukin-2 for 4 days. These results suggest that the immune function of cells in malignant effusions may be depressed due to a low population of cytotoxic T cells, low NK activity and increased suppressor T cells, while the local administration of interleukin-2 may induce LAK cells. Therefore, effective local immunotherapy for malignant effusions should not only augment effector cells, but also inhibit suppressor cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102920     DOI: 10.1007/bf00730624

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  14 in total

1.  Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

Authors:  M S Mitchell; R A Kempf; W Harel; H Shau; W D Boswell; S Lind; E C Bradley
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

2.  A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.

Authors:  R D'Acquisto; M Markman; T Hakes; S Rubin; W Hoskins; J L Lewis
Journal:  J Clin Oncol       Date:  1988-04       Impact factor: 44.544

3.  New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.

Authors:  M Torisu; M Katano; Y Kimura; H Itoh; M Takesue
Journal:  Surgery       Date:  1983-03       Impact factor: 3.982

4.  Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.

Authors:  R C Bast; J S Berek; R Obrist; C T Griffiths; R S Berkowitz; N F Hacker; L Parker; L D Lagasse; R C Knapp
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

5.  Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432.

Authors:  A Uchida; M Micksche
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

6.  Lymphocyte subpopulations in peripheral blood and malignant effusions of cancer patients.

Authors:  E Robinson; R Segal; Z Vesely; T Mekori
Journal:  Eur J Cancer Clin Oncol       Date:  1986-02

7.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

8.  Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients.

Authors:  S Arinaga; T Akiyoshi; H Tsuji
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

9.  Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2.

Authors:  S Takagi; K Chen; R Schwarz; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  3 in total

1.  Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.

Authors:  Arnaud Scherpereel; Bogdan Dragos Grigoriu; Marc Noppen; Thomas Gey; Bachar Chahine; Simon Baldacci; Jacques Trauet; Marie-Christine Copin; Jean-Paul Dessaint; Henri Porte; Myriam Labalette
Journal:  BMC Cancer       Date:  2013-07-02       Impact factor: 4.430

2.  Retrospective Analysis of Pediatric Hepatoblastoma With Tumor Rupture: Experience From a Single Center.

Authors:  Yu-Tong Zhang; Yu-Fei Zhao; Dian-Fei Yang; Jian Chang
Journal:  Front Pediatr       Date:  2022-03-22       Impact factor: 3.418

3.  Malignant and tuberculous pleural effusions: immunophenotypic cellular characterization.

Authors:  Lucia Maria Zanatta de Aguiar; Leila Antonangelo; Francisco S Vargas; Maria Cláudia Nogueira Zerbini; Maria Mirtes Sales; David E Uip; Paulo Hilário Nascimento Saldiva
Journal:  Clinics (Sao Paulo)       Date:  2008-10       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.